News | January 07, 2008

Young, Obese Women with PCOS at Risk for Coronary Atherosclerosis

January 8, 2008 – Young, obese women with polycystic ovary syndrome (PCOS) may be at increased risk for early subclinical coronary atherosclerosis, independent of the presence of traditional cardiovascular risk factors and novel inflammatory risk markers, according to a study by researchers at the University of Iowa published in the December issue of the Journal of Clinical Endocrinology and Metabolism.

The study involved 24 women, between 21 and 50 years of age, with PCOS and a body mass index of 30 or higher, and 24 weight- and age-matched controls without PCOS. Eight of 24 PCOS subjects, or 33 percent, and two of 24 controls, or 8 percent, were diagnosed with coronary artery calcium, an indicator of early-onset atherosclerosis.

Additionally, researchers found that the majority of women with detectable coronary artery calcium did not have traditional cardiovascular risk factors “and the presence of PCOS status per se appeared to contribute to this increased risk of coronary artery calcium,” said Rupal Shroff, M.D., one of the researchers at University of Iowa.

For more information: jcem.endojournals.org


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now